Compare Alcon AG (ALC) vs Barclays PLC (BCS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs Barclays PLC — how do they compare? Alcon AG trades at $75 (market cap $35.19B), while Barclays PLC trades at $27.87 (market cap $94.10B). The key difference: Barclays PLC is far larger — about 2.7× Alcon AG's market cap, and Barclays PLC pays the higher dividend (2.18%). Which is the better fit depends on your goals.
| ALC | BCS | |
|---|---|---|
Market Cap | $35.19B | $94.10B |
Sector | Health | Financials |
52-Week High | $90.12 | $28.56 |
52-Week Low | $62.02 | $19.36 |
Enterprise Value | $39.03B | — |
Dividend Yield | 0.49% | 2.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $71.81, up 3.26% today, with a bullish technical signal supported by moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.84, beating estimates, and raised its profit guidance on August 11, 2026, citing strong product launches. Revenue grew to $10.4B in 2025, though net income margin dipped to 9.42%. Valuation ratios include a P/E of 43 and P/S of 3.34, reflecting premium pricing.
Outlook is positive with analyst consensus at 54% buy ratings and a 27.8% upside target, but risks include margin pressure and high debt. The stock offers growth potential from innovation but faces competitive and macroeconomic headwinds.
Barclays PLC (BCS) trades at $27.93, down 0.89% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.90 exceeding the $0.89 estimate. Revenue grew to $29.14 billion in 2025, with a net income margin of 25.51%. Analyst consensus is 68% buy, though recent news highlights a securities class action investigation.
The outlook for BCS is positive given earnings momentum and a low P/E of 10.73, but risks include the legal investigation and rising costs noted in Q2 2026. Investment opportunity lies in valuation discount and dividend yield, while sentiment is mixed due to near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Barclays PLC
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →
